Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Business Model:
Revenue: $7.3M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Viking Therapeutics Information
Geographic Data
Address: 12340 El Camino Real
City: San Diego
State: CA
Zip: 92130
Country: US
Financial Info
Stage:
post ipo equity
Raised Last:
$141M
Raised Total:$24M
Social
Metrics
4,610,019Website Global Rank
1,985Website Monthly Traffic
Twitter Followers
Description
Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK0612, a first-in-class, orally available drug candidate type 2 diabetes. The Company’s second clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of cancer cachexia. Viking is also developing three novel preclinical programs targeted at metabolic diseases and anemia.
Contact Phone:
+18587044660
Contact Email:
Viking Therapeutics went public on 4/13/2015 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
4/13/2015
IPO Valuation:
$73M
Ticker Symbol:
VKTX
IPO Price:
$8/share
Amount Raised:
$24M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 4/2015 | IPO | $24M |
|
6/2018 | Post-IPO Equity | $140.9M | 8/2016 | Post-IPO Equity | $0 |
Aspire Capital Partners LLC Aspire Capital Partners LLC |
12/2017 | Post-IPO Equity | $14.8M | 5/2016 | Post-IPO Equity | $10.8M | 5/2014 | Debt Financing | 1 | $2.5M |
Ligand Pharmaceuticals Ligand Pharmaceuticals |
8/2016 | Post-IPO Equity | 1 | $12.5M |
Aspire Capital Partners LLC Aspire Capital Partners LLC |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
